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Abstract
CLEC5A/MDL-1, a member of the myeloid C-type lectin family expressed on macrophages and neutrophils, is critical for
dengue virus (DV)-induced hemorrhagic fever and shock syndrome in Stat1
2/2 mice and ConA-treated wild type mice.
However, whether CLEC5A is involved in the pathogenesis of viral encephalitis has not yet been investigated. To investigate
the role of CLEC5A to regulate JEV-induced neuroinflammation, antagonistic anti-CLEC5A mAb and CLEC5A-deficient mice
were generated. We find that Japanese encephalitis virus (JEV) directly interacts with CLEC5A and induces DAP12
phosphorylation in macrophages. In addition, JEV activates macrophages to secrete proinflammatory cytokines and
chemokines, which are dramatically reduced in JEV-infected Clec5a
2/2 macrophages. Although blockade of CLEC5A cannot
inhibit JEV infection of neurons and astrocytes, anti-CLEC5A mAb inhibits JEV-induced proinflammatory cytokine release
from microglia and prevents bystander damage to neuronal cells. Moreover, JEV causes blood-brain barrier (BBB)
disintegrity and lethality in STAT1-deficient (Stat1
2/2) mice, whereas peripheral administration of anti-CLEC5A mAb reduces
infiltration of virus-harboring leukocytes into the central nervous system (CNS), restores BBB integrity, attenuates
neuroinflammation, and protects mice from JEV-induced lethality. Moreover, all surviving mice develop protective humoral
and cellular immunity against JEV infection. These observations demonstrate the critical role of CLEC5A in the pathogenesis
of Japanese encephalitis, and identify CLEC5A as a target for the development of new treatments to reduce virus-induced
brain damage.
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Introduction
The Flavivirus genus includes the mosquito-borne dengue,
Japanese encephalitis and yellow fever viruses [1], infections of
which can result in clinical syndromes such as hemorrhagic fever
and encephalitis. There are four serotypes of dengue virus (DV),
which can give rise to severe hemorrhagic syndrome (dengue
hemorrhagic fever/DHF) and capillary leakage induced-hypovo-
lemic shock (dengue shock syndrome/DSS) [2]. On the other
hand, the Japanese encephalitis virus (JEV) serological group,
which includes West Nile virus (WNV) and St. Louis encephalitis
virus, is a major contributor to the occurrence of viral encephalitis
worldwide [3], with 50,000 new cases and 15,000 deaths per
annum [4]. JEV is the most prevalent cause of encephalitis and
although both inactivated [5] and live-attenuated [6] JEV vaccines
have been used in Asia for decades, these are not completely
effective against all the clinical isolates [7], and there are still
,35,000 reported cases of Japanese encephalitis (JE) resulting in
10,000 deaths each year [8]. Unlike DHF and DSS, JE victims
experience permanent neuropsychiatric sequelae, including per-
sistent motor defects and severe cognitive and language impair-
ments [9]. However, the molecular pathogenesis of JEV infection
is still unclear.
JEV-specific infiltrating T lymphocytes and JEV-neutralizing
IgM and IgG are believed to play major roles in the recovery and
clearance of the virus, while microglia were shown to secret
massive amounts of cytokines following JEV infection [10]. While
JEV infects and kills neuron directly [11], viral replication within
microglia/glia leads indirect neuronal killing via secretion of
cytokines (such as TNF-a) and soluble mediators to cause neuronal
death [11]. One of the key factors in indirect neuronal cell death
during JE is the uncontrolled overactivation of microglia cells [12].
However, the molecular mechanism of JEV-induced microglia
activation is unclear, thus we are interested to identify the key
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release from microglia. This information may help in the
development of specific treatments for JEV-induced neuroinflam-
mation.
CLEC5A (also known as myeloid DAP12-associating lectin
(MDL-1) [13]) contains a C-type lectin-like fold similar to the
natural-killer T-cell C-type lectin domains, and associates with a
12-kDa DNAX-activating protein (DAP12) [14] on myeloid cells
such as monocytes, macrophages and neutrophils, but not
monocyte-derived dendritic cells. Moreover, we have shown
dengue virus (DV) can bind and activate CLEC5A and induce
the phosphorylation of DAP12 [15], which is responsible for
CLEC5A/MDL-1-mediated signaling [13]. Unlike conventional
C-type lectin receptors (CLRs), such as DC-SIGN/CLEC4L,
DC-SIGNR/CLEC4M, and mannose receptor/CLEC13D/
CD206 [16], which are all involved in dengue virus (DV) entry
into target cells, CLEC5A regulates virus-induced proinflamma-
tory cytokine release from macrophages [15]. In addition,
blockade of CLEC5A can prevent autoimmune inflammation in
collagen-induced arthritis via downregulating osteoclast activa-
tion, suppressing cell infiltration of joints, and attenuating
proinflammatory cytokine release [17]. These observations
indicate that CLEC5A is a critical molecule to regulate
inflammatory reactions triggered by pathogens and autoantigens.
We thereby went on to determine whether CLEC5A is involved
in JEV-induced proinflammatory cytokine release from microglia
and bystander neuronal damage. Here, we demonstrate that JEV
infects and replicates in peripheral macrophages and microglia.
Moreover, blockade of CLEC5A dramatically reduces bystander
neuronal damage and JEV-induced proinflammatory cytokine
secretion from macrophages and microglia. Furthermore, pe-
ripheral administration of anti-CLEC5A mAb attenuates neuro-
nal cell death, inhibits JEV-bearing infiltrating cells into CNS,
and restores the expression of tight junction proteins and BBB
integrity. These results suggest that CLEC5A is a promising
therapeutic target to control neuroinflammation during viral
encephalitis.
Results
JEV activates macrophages to secrete proinflammatory
cytokines via CLEC5A
Reverse-transcription PCR (RT-PCR) using cDNA templates
from the human microglial cell line CHME3, macrophage-like cell
line U937, and CD14
+-derived macrophages (MoM) revealed the
presence of a dominant transcript (CLEC5A) and an alternatively
spliced variant (CLEC5A_S) lacking 23 amino acid (aa) residues
within the stalk region of CLEC5A (Figure S1A & S1B). Similarly,
murine CLEC5A_S (mCLEC5A_S) lacks 25 aa from the
corresponding region of murine CLEC5A (mCLEC5A) [18].
ELISA showed that human CLEC5A and mCLEC5A, but not
the alternatively spliced variants or structurally related members of
the CLEC family, are able to interact with JEV (Figure 1A). The
differential abilities of CLEC5A and CLEC5A_S to bind JEV
were further confirmed by immunoprecipitation (Figure S1C).
This observation demonstrates that the stalk region of CLEC5A
plays a critical role in binding to JEV. Incubation of macrophages
with JEV was shown to induce the phosphorylation of DAP12
(Figure S1D), a CLEC5A-associated adaptor protein with an
ITAM motif contributing to signal transduction. While UV-
inactivated JEV-induced DAP12 phosphorylation lasted for only
2 h, DAP12 phosphorylation was detectable for at least 24 h
following infection with live JEV, indicating DAP12 phosphory-
lation is enhanced by JEV replication (Figure 1B). Compared to
live JEV, UV-inactivated JEV only induced transient DAP12
phosphorylation and low amounts (less than 50 pg/ml) of TNF-a
and IL-6 secretion (data not shown). This indicates that virus
particles released from JEV-infected macrophages can continually
activate DAP12 and induce cytokine release. Furthermore,
knockdown of CLEC5A using the short hairpin RNA (shRNA)
pLL3.7/CLEC5A [15] abolished DAP12 phosphorylation (Figure
S1E), suggesting that JEV-triggered DAP12 phosphorylation is
mediated via CLEC5A.
We further investigated whether JEV could also infect and
activate human CD14
+-monocyte derived macrophages (MoM).
Although JEV was found to be less efficient than DV in infecting
macrophages, only JEV infected the human neuroblastoma cell
line HTB11 (Figure S2A), suggesting that JEV is both myelotropic
and neurotropic. Moreover, JEV activates MoM to secret
proinflammatory cytokines, and anti-CLEC5A mAb blocked the
release of TNF-a and MCP-1 but not IFN-a, from JEV-infected
MoM (Figure 1C) and murine bone marrow-derived macrophages
(BMM) from Stat1
2/2 mice (Figure S2B&S2C). The critical role of
CLEC5A in JEV infection was further confirmed by incubating
JEV with BMM derived from Stat1
2/2/Clec5a
2/2 mice (Figure
S3). Compared to Stat1
2/2/Clec5a
+/+ mice, BMM from Stat1
2/2/
Clec5a
2/2 mice secreted significantly less TNF-a and MCP-1 in
response to JEV infection, while levels of IFN-a secretion were
very similar (Figure 1D). These findings further confirm the critical
role of CLEC5A in the JEV-induced inflammatory reaction.
Blockade of CLEC5A inhibits JEV-induced neuronal death
in mixed glial cell culture
Since astrocytes (glial cells) and microglia (cerebral residential
macrophages) are major sources of proinflammatory cytokines
during cerebral inflammation [11,12,19], we went on to
investigate the role of CLEC5A in JEV-induced neuroinflamma-
tion in Stat1
2/2 microglia and mixed glia cells. We found that
CLEC5A is expressed on microglia (Figure 2A) as determined by
immunohistochemistry staining. We further isolated the mononu-
clear cells (including hematopoietic and non-hematopoietic cells)
by Percoll-gradient centrifugation [20] from naı ¨ve mice to
Author Summary
Japanese encephalitis (JE) is one of the most common
forms of viral encephalitis worldwide, and the common
complication post viral encephalitis is permanent neuro-
psychiatric sequelae resulting from severe neuroinflamma-
tion. However, specific treatment to inhibit JEV-induced
neuroinflammation is not available. We found that JEV
interacts directly with CLEC5A, a C-type lectin expressed
on the myeloid cell surface. This observation led to two
major findings; first, we demonstrate that JEV activates
macrophages and microglia via CLEC5A, and blockade of
CLEC5A reduces bystander neuronal damage and JEV-
induced proinflammatory cytokine secretion from macro-
phages and microglia. Second, peripheral administration of
anti-CLEC5A mAb does not only inhibit JEV-induced BBB
permeability, but also reduces the numbers of activated
microglia and cell infiltration into the CNS. The attenuation
of neuronal damage and reduced viral load correlate with
the suppression of inflammatory cytokines TNF-a, IL-6, IL-
18, and MCP-1 in the CNS. Our studies provide new
insights into the molecular mechanism of neuroinflamma-
tion, and reveal a possible strategy to control neuroin-
flammation during viral encephalitis.
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PLoS Pathogens | www.plospathogens.org 2 April 2012 | Volume 8 | Issue 4 | e1002655Figure 1. JEV interacts with CLEC5A and induces cytokine secretion via CLEC5A. (A) Interaction of JEV with human and murine CLEC5A.Fc
fusion proteins was determined by ELISA. Anti-E Ab is a positive control to confirm the capture of JEV particles; HuIgG1: human IgG1. Data are
expressed as means 6 s.e.m. for three independent experiments; two-tailed Student’s t-tests were performed. (B) The kinetics of DAP12
phosphorylation induced by JEV (m.o.i.=2) and ultraviolet-inactivated JEV (UV-JEV) in human macrophages were determined by western blotting
(h.p.i., hours post infection). The intensities of pDAP12 bands were quantified with MetaMorph software (Molecular Devices) and its relative intensity
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is expressed on the surface of F4/80
+ tissue macrophages (90%),
CD11b
+ myeloid cells (65%), and CD45
+ cells (50%; predomi-
nantly in CD45
low hematopoeitic) (Figure 2B).
Due to the resistance of wild type mice to JEV infection,
previous studies in relation to JEV-induced brain damage have
utilized intracranial (i.c.) injection of JEV to deliver virus directly
to the CNS [21,22]. However, this approach causes mechanical
damage to the BBB and thus cannot be used to address the
mechanisms of JEV-induced changes in BBB permeability and the
associated entry of virus into the CNS. Since Stat1
2/2 mice are
sensitive to JEV infection even without i.c. puncture, and are able
to develop protective immunity after JEV challenge, these animals
provide a useful model to test the protective effects of vaccines
against JEV and other pathogens which are unable to infect wild
type mice. We set up microglia (95% purity) and mixed glial cell
(approximately 85% astrocytes and 10% microglia) cultures from
Stat1
2/2 mice to assess the potential involvement of CLEC5A in
regulating cerebral inflammation and neuronal death after JEV
infection (Figure S4). Immuno-staining with a mAb to JEV
nonstructural protein 3 (NS3) showed that ,30% of mixed glial
cells and ,10% of microglia were infected with JEV. However,
anti-CLEC5A mAb was unable to inhibit either NS3 expression
(Figure 2C) or virus replication (Figure 2D), suggesting that
CLEC5A was not involved in JEV entry into these cells.
It has been reported that both JEV-infected astrocytes and
microglia release multiple bio-active factors, thereby giving rise to
secondary glial activation and neuronal injury [11,12]. We
therefore investigated the release of proinflammatory cytokines
from JEV-infected neurons, mixed glia and microglia cultures.
Cells were preincubated with anti-CLEC5A mAb for 1 h, followed
by incubation with JEV at 37uC for 1 h, and supernatants were
harvested to determine cytokine release at 24 h post-infection. We
found that TNF-a and MCP-1 were produced primarily by
microglia, and abundant IL-6 was released by JEV-infected mixed
glia (Figure 2E), while JEV-infected neurons only released trace
amount of these cytokines (Figure 2E). This observation is in
accord with a previous report that JEV-infected astrocytes produce
IL-6, but not TNF-a [11]. In our study, pre-incubation with the
anti-CLEC5A mAb mediated significant reductions in cytokine
release (Figure 2E); we therefore investigated whether anti-
CLEC5A mAb could prevent neuronal death during JEV
infection. Direct incubation of neurons with JEV caused 40% cell
damage (live cell count reduced from 171623 to 93627)
(Figure 2F), while UV-irradiated conditioned media (in the
absence of anti-CLEC5A mAb) from JEV-infected mixed glia
(UV-JEVCM; from Figure 2E) caused 80% cell damage (from
162619 to 2767 live cells) (Figure 2G). This indicated that soluble
mediators released from JEV-infected mixed glia are more toxic
than JEV per se to neurons. In addition, anti-CLEC5A mAb
protected approximately 50% of neurons from UV-JEVCM-
induced cell damage (from 162619 to 76612 live cells), but was
ineffective in protecting neurons from direct JEV infection
(Figure 2F). Previous studies demonstrated that TNF-a released
by microglia plays a critical role in JEV-associated neurotoxicity
[11], while MCP-1 secreted by microglia can recruit inflammatory
cells to cause neuronal damage [12]. Therefore, the anti-CLEC5A
mAb-mediated protective effect may occur via blocking the release
of TNF-a, MCP-1, and other yet-defined bio-active factors from
JEV-infected mixed glial cells and microglia.
CLEC5A regulates JEV–induced BBB disintegrity
While wild type mice only respond to high dose JEV challenge
(1610
5 pfu/mouse) with intracranial (i.c.) puncture (Figure S5A),
Stat1
2/2 mice are sensitive to low dose JEV-induced lethality
without the need for i.c. puncture (Figure S5B). Thus Stat1
2/2
mice were used as an in vivo model system to test whether anti-
CLEC5A mAb could maintain BBB integrity, which is known to
be damaged by virus-induced neuroinflammation [23,24]. Chang-
es in BBB integrity over time following JEV challenge, as revealed
by
99mTc-DTPA brain SPECT/CT imaging, showed that JEV
infection gave rise to increased BBB permeability from day 3 to
day 7 post infection (Figure 3A&B). This effect was reduced
(during day 3 to day 5) and normal BBB permeability was restored
on day 7 in response to treatment with anti-CLEC5A mAb. The
integrity of the BBB after anti-CLEC5A mAb treatment on day 7
was further confirmed by the Evans blue assay (Figure 3C). Since
tight junctions are critical in the regulation of BBB permeability,
and their disruption is a hallmark of CNS abnormalities [25], we
measured the expression of tight junction proteins (such as ZO-1,
Occludin and Claudins) and of adhesion molecules (such as JAM-1
and ICAM-1) known to be important for recruitment of
inflammatory cells. In JEV-infected mice (treated with isotype
mAb), the expression of ZO-1, Occludin, Claudin-1, and Claudin-
5 was downregulated, while the expression of ICAM-1 was
upregulated. However, the expression of junctional adhesion
molecule (JAM-1) was not changed after JEV infection (Figure 3D).
Interestingly, anti-CLEC5A mAb restored the expression of tight
junction proteins and suppressed JEV-induced upregulation
ICAM-1 (Figure 3D). Moreover, the increased BBB permeability
in JEV-infected mice was accompanied by perivascular cuffing,
while anti-CLEC5A mAb reduced the numbers of infiltrating foci
(Figure 3E). This demonstrates that peripheral administration of
anti-CLEC5A mAb is able to restore BBB integrity to prevent cell
infiltration.
Blockade of CLEC5A attenuates myeloid cell infiltration
into CNS
We further isolated mononuclear cells (MNCs) from the JEV-
infected Stat1
2/2 mice brain by Percoll gradient [20] to analyze
the cell lineages. At day 5 after JEV infection, most of the
infiltrating cells are F4/80
+CD11b
+ myeloid cells (left column,
Figure 4A). Peripheral administration of anti-CLEC5A mAb
efficiently inhibits the infiltration of F4/80
+ CD11b
+ myeloid cells
(right column, Figure 4A).
It has been shown that CD11b
+/CD45
+ cells contribute to the
pathogenesis of West Nile virus (WNV) encephalitis [26], thus
triple-color staining (CD11b/CD11c/CD45) was used to gate the
CD11c
2 population to distinguish residential microglia (R1) and
infiltrating myeloid cells (R1) (Figure 4B). To determine the source
of CD45
+CD11b
+ myeloid cells, carboxyfluorescein succinimidyl
ester (CFSE) was injected into peritoneum (i.p.) at day 2 post JEV
to that of the band of respective corresponding DAP12 and are shown under each picture. (C) Different amounts of antibody 0.1 mg( 2mg/ml;
0.013 mM), 1 mg (20 mg/ml; 0.13 mM) and 10 mg (200 mg/ml; 1.3 mM) were incubated with MoM before addition of JEV. Dose-dependent inhibition of
cytokine release from JEV-infected MoM by anti-CLEC5A mAbs (clones: 2B8H11, 6E11A8, 7F3G2) were determined using ELISAs at 48 h post infection.
mIgG1 was used as an isotype control. (D) Bone marrow-derived macrophages (5610
5 cells/well) from Clec5A
2/2 Stat1
2/2 and Clec5A
+/+ Stat1
2/2
mice were infected with JEV (m.o.i.=2) and supernatants were harvested at 48 hr after JEV infection for cytokine measurement. Data were collected
and expressed as mean 6 s.e.m. from at least three independent experiments. Two-tailed Student’s t-tests were performed.
doi:10.1371/journal.ppat.1002655.g001
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PLoS Pathogens | www.plospathogens.org 4 April 2012 | Volume 8 | Issue 4 | e1002655Figure 2. Blockade of CLEC5A inhibits neuronal death induced by supernatant from JEV-infected Stat1
2/2 murine mixed glial cell
culture. (A) Tissue sections of human perilesional brain cortex from glioblastoma multiforme were stained with CLEC5A mAb (20 mg/ml) and isotype
control. CLEC5A staining was observed under a light microscope (Nikon) and photographed. (B) Detection of CLEC5A
+ cells in F4/80
+, CD11b
+ and
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+ cells (Figure S6A). All
the peripheral blood cells were labeled with CFSE at day 5 post
infection whether treated with isotype or anti-CLEC5A mAb
(Figure S6B). In addition, intraperitoneal injection of CFSE was
unable to label CNS MNCs without intracranial (i.c.) puncture
(mode III, Figure S7B), nor when i.c. puncture was performed at 2
days after i.p. injection of CFSE (mode II, Figure S7B), even
though simultaneous CFSE i.p. injection and i.c. puncture (mode
I, Figure S7B) can label intracranial MNCs weakly. This indicates
that CFSE is either degraded or excreted within 48 hours.
We then analyzed the intracranial MNCs isolated from JEV-
infected Stat1
2/2 mice (Figure 4B). We found that approximately
5610
4 and 1.5610
3 CD45
+ cells were found in Percoll-gradient
purified MNCs from mice treated with isotype and anti-CLEC5A
mAb, respectively. Moreover, anti-CLEC5A mAb was able to
suppress the infiltration of CD11b
+CD45
hi cells (R1) into CNS, as
well as the proliferation of CD11b
+CD45
low cells (R2) after JEV
infection (upper row, Figure 4B). It is interesting to note that all the
CD11b
+CD45
low cells are CFSE negative, while most of the
CD11b
+CD45
hi cells are CFSE positive (lower row, Figure 4B).
These results suggested that the CD11b
+CD11c
2CD45
hi popula-
tion (R1) are the infiltrating inflammatory myeloid cells from
peripheral blood, while the CD11b
+CD11c
2CD45
low (R2) are the
resident microglia.
It has been demonstrated that CD45
+CD11b
+Ly6C
hi cells have
properties of inflammatory monocytes [27], and CLE-
C5A
+CD11b
+Gr1
+ cells are responsible for DV-induced septic
shock in ConA-primed mice [28], thus we further characterized
CD45
+ populations by detecting the expression of CLEC5A and
Gr1 (comprising Ly6C and Ly6G). We found that all the
CD45
hiCD11b
+ population expresses Ly6C, while 15% of the
CD45
hiCD11b
+ population also expresses Ly6G (Figure 4C).
Moreover, CLEC5A is highly expressed in CD45
hiCD11b
+
infiltrating inflammatory myeloid cells (45%), while only 5% of
CD45
lowCD11b
+ cells express CLEC5A (Figure 4D). This
observation suggests that the majority of the infiltrating inflam-
matory cells are CD45
hiCD11b
+Ly6C
+CLEC5A
+, while periph-
eral administration of anti-CLEC5A mAb efficiently reduces the
numbers of inflammatory myeloid cells and suppresses the
proliferation of resident macrophages in the CNS (R2).
Blockade of CLEC5A attenuates CNS inflammation
To determine whether anti-CLEC5A mAb can suppress brain
inflammation, viral load was measured in the sera and tissue
extracts collected from mice at day 3 and day 5–7 post JEV
infection. Short term viremia was observed at day 3 post infection,
with all the viruses being cleared from peripheral blood at day 5–7
post infection (Figure 5A). In contrast, JEV titers in spleen and
brain were maintained at a high level from day 3 to day 7 post
infection. Anti-CLEC5A mAb reduced viral load in the brain at
day 5–7 (p=0.009) but was ineffective in spleen (Figure 5A),
correlating with reduced NS3 expression in the brain at day 5 post
infection (Figure 5B). While JEV infection increased the numbers
of MNCs in brain (from 0.8–1610
4 to 1–2610
5/brain), anti-
CLEC5A mAb reduced the numbers of MNCs (2–3610
4/brain)
and NS3-bearing infiltrating myeloid cells (R1) and microglia (R2)
(Figure 5C). To further confirm the replication of JEV in R1 and
R2 populations, reverse-transcription PCR was used to quantitate
the JEV copy numbers in each population after sorting by FACS
(Figure 5D). As shown in Figure 5D, inflammatory myeloid cells
(R1) bear higher copies of viral RNA than resident microglia (R2).
This result suggests that anti-CLEC5A mAb is able to reduce
neuroinflammation by suppressing the infiltration of JEV-positive
myeloid inflammatory cells into CNS.
We also found that JEV induced the release of TNF-a, IL-6,
MCP-1 and IL-18 into the peripheral blood and CSF at day 5–7
post infection, whereas anti-CLEC5A mAb caused significant
suppression of cytokine levels (Figure 5E&F). Since TNF-a and IL-
18 are responsible for the cytotoxic and inflammatory responses in
a variety of neuropathological conditions [12,19,29,30], and
MCP-1 is a potent chemoattractant for monocytes and dendritic
cells [31], reduced cytokine levels in the CNS following anti-
CLEC5A mAb treatment would be expected to limit neuronal
damage. We found that the populations of TNF-a
+ (Figure 5G,
upper panel) and IL-6
+ (data not shown) CD11b
+/F4/80
+ cells
(infiltrated monocytes and resident microglia), as well as IL-6
+
(Figure 5G, lower panel) and TNF-a
+ (data not shown) CD11b
+/
CD45
+ (R1 and R2) cells were also reduced in JEV-infected mice
following anti-CLEC5A mAb treatment at day 5–7 post infection.
Thus, even though peripheral administration of anti-CLEC5A
mAb is unable to inhibit viral replication, it can reduce viral load
and attenuate inflammation in the CNS via inhibition of cellular
infiltration and proinflammatory cytokine secretion.
Anti-CLEC5A mAb reduces neuron damage and reduces
astrocytosis
At day 5 post JEV infection, ischemic, shrunken and damaged
neurons and Purkinje cells were observed in the cortical region of
the cerebrum (Figure 6A, middle upper panel) and cerebellum
(Figure 6B, middle lower panel), respectively. The JEV-induced
pathological changes were inhibited by anti-CLEC5A mAb
(Figure 6A, right upper & lower panels). Moreover, JEV infection
caused astrocytosis, an abnormal increase in the number of
astrocytes due to the destruction of nearby neurons in the CNS, in
cerebrum and cerebellum as determined by glial fibrillary acidic
protein (GFAP) staining (Figure 6B). Upregulation of GFAP and
increased astrocyte proliferation in cerebrum (Figure 6B; middle
upper panel) and cerebellum (Figure 6B; middle lower panel) were
CD45
+ mononuclear cells isolated from naı ¨ve murine brain. (C) Viral antigen NS3 (red; cells counterstained with Hoechst (blue)) was detected in JEV-
infected microglia or mixed glia (m.o.i.=5) in the presence of anti-CLEC5A mAb (clone: 3E3G4; 200 mg/ml, 1.3 mM) at 48 h post infection. Scale bars,
50 mm. (D) The kinetics of virus replication were unaffected by anti-CLEC5A mAb (3E3G4). Viral titers in culture supernatants were determined by
plaque assay. Data were collected from three independent experiments. (E) anti-CLEC5A mAb (clone: 3E3G4; 200 mg/ml, 1.3 mM) were incubated with
mixed glia or microglia before addition of JEV. Cytokine secretion from JEV-infected mixed glia and microglia was harvested and analyzed by ELISA at
48 h p.i.. (F) An immunocytochemical analysis (anti-tubulin b III isoform mAb) shows the morphology of JEV-infected neurons (m.o.i.=5) in the
presence of anti-CLEC5A mAb or isotype matched control at 24 h post JEV infection. (G) An immunocytochemical analysis (anti-tubulin b III isoform
mAb) shows the morphology of neurons after incubation with UV-inactivated conditioned medium (CM) from JEV-infected mixed glia (UV-JEVCM)
(m.o.i.=5), in the presence of isotype matched control (UV-isotype_JEVCM) or anti-CLEC5A mAb (UV-CLEC5A mAb_JEVCM) for 24 h. The morphology
of neurons was observed by immunocytochemical staining with anti-Tubulin b III isoform Ab (TU20), and visualized under a light microscope (Nikon).
Five fields of views were randomly photographed, and the numbers of live neurons were counted and represented as mean 6 s.e.m. (under each
picture) for three independent experiments. Significance compared to mock treatment was tested using a two-tailed Student’s t-test (Figure 2F). In
Figure 2G, the P,0.0001 indicates a significant difference in UV-MOCK CM vs. UV-JEVCM; P=0.0007 indicates a significant difference in UV-Isotype
JEVCM vs. UV-CLEC5A mAb JEVCM.
doi:10.1371/journal.ppat.1002655.g002
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antibody, while anti-CLEC5A mAb downregulated reactive
astrocytosis substantially (Figure 6B, right upper & lower panels).
Thus, peripheral administration of anti-CLEC5A not only
suppresses neuroinflammation, but also increases the survival of
neuronal and Purkinje cells.
Blockade of CLEC5A prevents JEV-induced lethality and
allows development of adaptive immunity against JEV
Investigation of the ability of anti-CLEC5A mAb to protect
Stat1
2/2 mice from JEV-induced lethality revealed that 50% of
Stat1
2/2 mice that succumbed to JEV infection died in the early
stages (6 days post infection), and all the mice died within 9 days
post infection. In contrast, administration of anti-CLEC5A mAb
from day 0 (150 mg/mouse on days 0, 2, 4, 6, and 8) protected
mice from early lethality (80% survival), and ,50% mice survived
for at least 16 days post infection (Figure 7A). We went on to
determine whether administration of anti-CLEC5A mAb inhibited
adaptive immunity against JEV. All the mice that survived JEV-
induced lethality were found to have sero-conversion from day 12
post infection (Figure 7B), suggesting that suppression of JEV-
induced inflammation by anti-CLEC5A mAb did not prevent
development of humoral immunity against the virus. This was
further confirmed by plaque reduction neutralization tests
(PRNT), where serum from surviving mice efficiently neutralized
JEV infection (Figure 7C). In addition, the proinflammatory
cytokine levels at day 7–9 post infection were much lower in the
sera of asymptomatic mice (Figure 7D). These mice also exhibited
JEV-specific T-cell responses; high levels of IFN-c were released
from JEV-challenged splenocytes, while IFN-c was almost
undetectable in cells from uninfected mice under the same
conditions (Figure 7E). It is interesting to note that virus was
cleared from the spleen and CNS at day 21 post infection in
surviving mice (Figure 7F), suggesting that the host can eradicate
JEV after anti-CLEC5A mAb treatment. Thus, blockade of
CLEC5A can suppress proinflammatory reactions without inter-
fering with the development of anti-JEV immunity, making
CLEC5A a promising target for the treatment of flaviviral
infections in the future.
Discussion
There is growing evidence that microglial cell activation
contributes to neuronal damage and neurodegenerative diseases
[32]. Following pathogen invasion, these cells play a role in the
clearance of cell debris from damaged tissue, but also secret
inflammatory cytokines, which are key mediators of the neurode-
generation associated with both acute and chronic CNS
pathologies [33]. Our observation that blockade of CLEC5A on
microglia attenuates the neuronal damage caused by the
supernatants from mixed glia culture in vitro further demonstrates
the contribution of microglia to JEV-induced neuronal death.
Moreover, peripheral administration of anti-CLEC5A mAb was
found to preserve BBB integrity, inhibit cellular infiltration into the
brain, and reduce neuronal death in vivo. This may be attributed
the fact that the anti-CLEC5A mAb can enter the CNS when the
permeability of BBB is increased during the acute stage of
infection, where intracranial anti-CLEC5A mAb can inhibit
microglia activation and attenuate neuroinflammation.
Although JEV can directly infect neurons and cause cell
damage, the soluble mediators from CLEC5A
+-activated microg-
lia and infiltrating myeloid cells seem to be the major cause of
neuron damage (bystander neuronal damage), since the inhibition
of JEV-induced neuroinflammation by anti-CLEC5A mAb does
not arise from interactions with cells, such as astrocytes and
gangliocytes in the CNS, or from prevention of neuron damage
caused by direct JEV infection. Even though anti-CLEC5A mAb
has relatively mild inhibitory effects on cytokine release in JEV-
infected macrophages (Figure 1) and microglia (Figure 2), it can
inhibit the permeability change of BBB (Figure 3), reduce cell
infiltration into the CNS (Figure 3 & 4) and protect mice from
JEV-induced lethality. This may due to the blocking effect of anti-
CLEC5A mAb to inhibit the release of yet-discovered soluble
mediators which are critical to control BBB permeability and
neuronal death. The alternative is that anti-CLEC5A mAb can
inhibit the infiltration of CLEC5A
+ MNCs which are pathogenic
to CNS, thus suppressing neuronal inflammation and reducing
lethality. The possibility of a direct effect on MNCs is supported by
the observation that DV can activate CLEC5A
+ CD11b
+Gr-1
+
immature myeloid cells to induce shock in ConA-treated mice
[28]. Finally, anti-CLEC5A mAb may block the interaction of
CLEC5A
+ cells with endogenous ligands to reduce neuroinflam-
mation. It has been shown that CLEC5A is critical for collagen-
induced autoimmune arthritis (CIA), and CLEC5A-deficient mice
are resistant to CIA. This observation suggests that the yet-
characterized CLEC5A endogenous ligand(s) is (are) able to
activate CLEC5A
+ cells to induce inflammatory reactions [17].
Therefore, the peripheral administration of anti-CLEC5A mAb
may inhibit JEV-induced inflammation via blocking multiple
pathways.
It is interesting to note that anti-CLEC5A mAb is able to inhibit
the secretion of IL-18, which is one of the key factors responsible
for neuroinflammation and neurodegeneration [29]. IL-18
enhances caspase-1 expression and induces the production of
matrix metalloproteinase (MMPs) and other proinflammatory
cytokines such as TNF-a and IL-1b [34,35]. Upregulation of IL-
18 was detected in the sera and CNS of JEV-infected mice, thus
the potent protective effects of anti-CLEC5A mAb in JEV-induced
neuroinflammation can be attributed, at least in part, to inhibition
of IL-18 secretion in the periphery and in the CNS; i.e., CLEC5A
Figure 3. Effect of anti-CLEC5A mAb on dynamic changes in the BBB during JEV infection. (A) Stat1
2/2 mice were injected intravenously
with
99mTc-DTPA to enable brain SPECT/CT imaging, before (D0) or after JEV challenge (100 pfu/mouse), in the presence of anti-CLECA5 mAb (3E3G4)
or an isotype matched control. Antibody (150 mg/mouse) was administrated intraperitoneally on days 0, 2, 4, 6 and 8 to determine any protection
effects in reduction to BBB permeability. Image datasets were reconstructed using the ordered-subset expectation maximization algorithm with
standard-mode parameters. (B) The extent of BBB breakdown was calculated as the ratio of the mean counts/pixel in the region of the brain with the
greatest accumulation of radiotracer divided by the mean counts/pixel in the neck muscle (b/m ratio). (C) Changes in BBB permeability at day 7 post
JEV infection (100 pfu/mouse) were determined by Evans Blue assay. (D) Brains of JEV-infected mice (n=5) with isotype control or anti-CLEC5A Ab
treatment were harvested at day 5 and day 9 post infection to analyze the expression of transcripts encoding tight junction proteins and adhesion
molecules by quantitative real-time PCR. For tight junction proteins, y-axis units represent the expression level of each target gene relative to mock
control after internal control normalization; the expression level of adhesion molecules is displayed as fold increase relative to mock control. Two-
tailed Student’s t-tests were performed. (E) H&E staining of murine cerebral cortex at day 5 after JEV infection revealed the inhibitory effect of anti-
CLEC5A mAb on perivascular cuffing. Scale bars, 200 mm. Five random fields of views in medium power field (original magnification (OM)6200) were
photographed, and the numbers of foci and vessel cross sections in each sample were counted, summed up and represented as mean 6 s.e.m.
(under each picture) of four independent experiments.
doi:10.1371/journal.ppat.1002655.g003
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mononuclear cells (MNCs) isolated from JEV-infected murine brain tissue with isotype control or anti-CLEC5A mAb treatment at day 5 post infection;
cell populations were determined by staining specific cell surface markers. (B) MNCs were further characterized by determining expression levels of
CD45 in the CD11b
+CD11c
2 population to distinguish inflammatory myeloid cells from peripheral (R1, CD45
hi) and resident microglia (R2, CD45
low),
respectively (upper panel). Recruitment of CD11b
+CD45
+ cells into brain of JEV-infected mice was tracked by in vivo labeling of blood cells with
fluorescent dye CFSE. (C) Analysis of the CD45
+CD11b
+ population for Ly6C and Ly6G expression revealed the major Ly6C
+ and minor Ly6G
+
populations in CD11b
+CD45
hi peripheral inflammatory myeloid cells. The percentages indicate the specific region in CD11b
+-gated cells (the
collected CD11b
+ cells in the isotype group and CLEC5A mAb treatment group are approximately 25,000 cells and 1,000 cells, respectively.) Three
independent experiments with three mice per group were performed and representative FACS plots are shown. (D) CLEC5A expression in peripheral
inflammatory myeloid cells (R1-gated; CD11c
2CD11b
+CD45
hi) and residential microglia (R2-gated; CD11c
2CD11b
+CD45
low) isolated from JEV-infected
murine brain.
doi:10.1371/journal.ppat.1002655.g004
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infection.
After anti-CLEC5A mAb treatment, approximately 50% of
JEV-infected Stat1
2/2 mice became asymptomatic and survived
for at least 21 days post infection, while the others remained weak
and died gradually within 12 days. While the titers of the
neutralizing antibody were similar in the weak and asymptomatic
groups (Figure 7C), the proinflammatory cytokine levels at 7–9
days post infection were much lower in the sera of asymptomatic
mice (Figure 7D). This indicates that JEV-induced neuroinflam-
mation is the key parameter in predicting the outcome of JEV
infection [19], and that effective suppression of neuroinflammation
in the acute stage is critical to increasing survival and preventing
neurological sequelae. This observation also suggests that
administration of anti-JEV antiserum to patients during the acute
stage of infection may be futile, and this argument is supported by
the observation that injection of a neutralizing cross-reactive mAb
against JEV E protein causes early death in JEV-infected mice
[36]. Even though the direct relevance of this Stat1
2/2 mouse
model in relation to human infection with JEV needs to be further
confirmed, data for in vivo protection of CLEC5A mAbs still shed
light on its therapeutic potential for blocking neuroinflammation.
Previous studies have shown that CLEC5A can interact with all
the four serotypes of DV [15,37], and here we have demonstrated
that CLEC5A also interacts with JEV (Figure 1A), but not with
other viruses such as influenza virus and EV-71 (Figure S8). In
addition, anti-CLEC5A mAb can inhibit inflammatory reactions
in human macrophages in response to the structurally related West
Nile virus (WNV) (Figure S9). Thus, CLEC5A may play a critical
role in the pathogenesis of all the flaviviral infections.
This study has clearly demonstrated that infiltration of
inflammatory cells into CNS correlates with increased BBB
permeability, suggesting that BBB integrity has a critical role in
limiting JEV-induced CNS inflammation. CLEC5A
+ microglia
and infiltrating myeloid cells appear to be essential for JEV-
induced inflammation of the CNS and neurological sequelae, and
anti-CLEC5A mAb efficiently suppressed the release of proin-
flammatory cytokines from microglia and macrophages, restored
BBB integrity and increased survival after JEV infection in mice.
The critical role of CLEC5A in JEV infection was further
confirmed by using Stat1
2/2Clec5a
2/2 mice, which are resistant to
JEV challenge (Figure S10). Together with our previous
observations that anti-CLEC5A mAb is able to prevent DV-
induced systemic vascular permeability and protect mice against
DV-induced lethal diseases [15]_ENREF_5, the data presented
here indicate that CLEC5A plays critical roles in the pathogenesis
of flaviviral infections via regulating vascular permeability and
suppressing myeloid cell activation.
Like most members of C-type lectin, their exogenous and
endogenous ligands are not identified yet. Since crystal structure of
CLEC5A reveals that CLEC5A forms homodimer on cell surface
[37], thus the binding of JEV to CLEC5A.Fc may similar to JEV
to CLEC5A on cell surface, though cells may also expressed other
C-type lectin to increase binding affinity. Recently, we have
developed an innate immunity receptor-based ELISA (IIR-EIA) to
determine the polysaccharide profiling [38] and dengue receptor
[15] based on C-type lectin.Fc fusion proteins, thus the
identification of CLEC5A as a JEV recognition receptor further
suggests that IIR-EIA is an useful tool to identify lectin ligands in
the future.
Materials and Methods
Ethics statement
Human monocytes were obtained from healthy donors at the
Taipei Blood Center of the Taiwan Blood Services Foundation,
under a protocol (PM-99-TP-075) approved by the IRB of the
Clinical Center of the Department of Health, Taiwan. Written
informed consent was obtained from all donors.
All animal studies were performed according to the animal
study protocol approved by the Animal Experimental Committee
of National Yang-Ming University, and in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Taiwanese Council of Agriculture.
The animal protocol was approved by the Institutional Animal
Care and Use Committee (IACUC) of National Yang-Ming
University (IACUC #1000519). All surgery was performed under
sodium pentobarbital anesthesia, and every effort was made to
minimize suffering.
Reagents
Chemical reagents were purchased from Sigma, culture media/
supplements from Invitrogen GIBCO and growth factors from
R&D Systems. Anti-CD14 microbeads were from Miltenyi Biotec
GmbH, while antibodies for FACS analysis were from BD
Pharmingen. Other antibodies were from Upstate Biotechnology
(anti-phosphotyrosine, clone 4G10), Santa Cruz (anti-human
DAP12 & anti-F4/80), Millipore (anti-tubulin b III isoform (TU-
20) mAb), and Cell Signaling (anti-glial fibrillary acidic protein).
Virus
The neurovirulent (RP-9) strain of Japanese encephalitis virus
(JEV), used for both in vitro and in vivo studies, was generated
from a Taiwanese isolate, NT109 [39]. Aedes albopictus C6/36 cells
and the baby hamster kidney fibroblast cell line BHK-21 were
used for viral propagation and viral titer determination, respec-
tively. Viral particles were purified from JEV-infected C6/36 cell
supernatant by sucrose gradient centrifugation (1/10 volume of
the 35% (v/v) sucrose buffer (10 mM Tris-HCL pH 7.5, 100 mM
NaCl and 1 mM EDTA), followed by ultra-centrifuging at
32,000 rpm for 3.5 hr, and resuspending the viral pellet in
0.5 ml PBS after removing the supernatant thoroughly.
Figure 5. Anti-CLEC5A mAb reduces viral load in the CNS and attenuates CNS inflammation. (A) Viral titer was determined by plaque
assay for sera and tissue homogenates from JEV infected mice with or without anti-CLEC5A mAb treatment (two-tailed Student’s t-tests). (B) The
extent of NS3 expression in the cortex was diminished after peripheral administration of anti-CLEC5A mAb at day 5 post JEV infection. Scale bars,
50 mm. Five random fields of views in medium power field (original magnification (OM)6200) were photographed, and the numbers of NS3
+ cells in
each sample were counted, summed up and represented as mean 6 s.e.m. (under each picture) of four independent experiments. (C) Numbers of
NS3
+ leukocytes (CD45
hiCD11b
+ and CD45
midCD11b
+) in JEV-infected brain were significantly reduced by administration of anti-CLEC5A mAb at day 5
post JEV infection. (D) Quantification of viral copies in CD45
hiCD11b
+ (R1) and CD45
lowCD11b
+ (R2) cells sorted from the brain of JEV-infected mice.
The average of total cell numbers in R1 and R2 were approximately 5610
4 and 2610
4, respectively, in the isotype treated group. Q-PCR assay was
performed on total RNA from each population and normalized with its respective internal control. Data were collected from four independent
experiments. Two-tailed Student’s t-tests were performed. Cytokines levels in the sera (E) and CSF (F) were measured by ELISA at day 5–7 post JEV
infection. The effects of CLEC5A mAb (3E3G4) and isotype control were compared using two-tailed Student’s t-tests. (G) Intracellular TNF-a and IL-6
were detected in CD11b
+ gated F4/80
+ and CD45
+ cells isolated from JEV-infected brain by flow cytometry.
doi:10.1371/journal.ppat.1002655.g005
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Human and murine pcDNA3.1 CLEC5A.Fc DNA constructs
were transfected into 293 FreeStyle cells (Invitrogen), and the
recombinant proteins were purified with Protein A beads. To
determine the CLEC5A-JEV interaction by ELISA, sucrose-
cushion-purified JEV particles (5610
6 pfu) were coated on
microtiter plates, and bound CLEC5A.Fc fusion proteins
(0.05 mg/mL; 100 mL/well) were detected with HRP-conjugated
anti-human IgG (Fc) (Jackson Immunoresearch) using 3,39,5,59-
tetramethylbenzidine (TMB) (BD Pharmingen) as substrate. For
Figure 6. Anti-CLEC5A mAb rescues JEV-induced neuronal damage. (A): JEV-induced pathological changes were examined by H&E staining.
Arrowheads indicate dysmrophic neurons in the cerebral cortex (upper panel) and damaged Purkinje cells in the cerebellum (lower panel), scale bars,
200 mm. (B) Neuronal damage induced-astrogliosis was characterized by GFAP staining, scale bars, 50 mm. For (A) and (B), tissues were harvested at
day 5 post JEV infection. Five random fields of views in medium power field (original magnification (OM)6200) were photographed, and the numbers
of dysmorphic neurons or GFAP
+ cells in cerebral cortex and cerebellum in each sample were counted, summed up and represented as mean 6
s.e.m. (under each picture) of four independent experiments.
doi:10.1371/journal.ppat.1002655.g006
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2/2 mice (8–10 weeks) was monitored for 16 days
after intraperitoneal inoculation of JEV (100 pfu/mice); data were collected from four independent experiments and are shown as Kaplan–Meier
survival curves with log rank test; n=20 for each group. (B) Titers of anti-JEV specific IgM and IgG antibodies in murine sera were determined by
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incubated with purified JEV particles (5610
6 pfu) at 4uC for 4 h
and then with 10 m1 of protein A–Sepharose beads for 2 h. The
immunocomplex was washed gently before fractionation on SDS–
PAGE, followed by transfer onto a nitrocellulose membrane and
probing with a mouse mAb specific for JEV envelope protein (E)
[39]. Immunoblots were developed with HRP-conjugated anti-
mouse IgG (Fab)92 (ab5887, Abcam), followed by enhanced
chemiluminescence detection reagents (Amersham).
Detection of DAP12 by immunoprecipitation and
immunoblotting
Macrophages (1610
6) were stimulated with JEV (m.o.i.=2) for
2 h, followed by resuspension in lysis buffer (50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 1% (v/v) Triton X-100, 0.1% (w/v) SDS,
5 mM EDTA, 10 mM NaF, 1 mM sodium orthovanadate, and
proteinase inhibitor cocktail (Roche)). Total cell extracts (100 mg)
were incubated with rabbit anti-DAP12 polyclonal antibody at
4uC for 4 h and then with Protein A–Sepharose for 2 h. The
immunocomplex was washed and fractionated on SDS–PAGE,
followed by transfer onto a nitrocellulose membrane and probing
with anti-phosphotyrosine antibody. Immunoblots were developed
with HRP-conjugated anti-mouse IgG (Cat. AP181P; Chemicon)
followed by enhanced chemiluminescence detection reagents (
Immobilon Western; Millipore). To determine the total amount of
DAP12 present on the blot, the membrane was stripped with Re-
Blot Plus Strong solution (Cat. 2504; Chemicon), and probed with
rabbit anti-DAP12 antibody.
Preparation of macrophages
For human macrophage preparation, peripheral blood mono-
nuclear cells (PBMCs) were isolated from the whole blood of
healthy human donors by standard density-gradient centrifugation
with Ficoll-Paque (Amersham Biosciences). After centrifugation
the buffy coat, containing leukocytes (PBMC) and platelets, was
further washed with PBS, and CD14
+ cells were purified using the
VarioMACS technique with anti-CD14 microbeads (Miltenyi
Biotec GmbH). Cells were then cultured in complete RPMI 1640
medium supplemented with 10 ng/ml human M-CSF (R&D
Systems) for 6 days [15]. For preparation of murine bone marrow-
derived macrophages, bone marrow cells were isolated from
femurs and tibias and cultured in RPMI 1640 complete medium
supplemented with 10% (v/v) fetal calf serum (FCS) and 10 ng /
ml of recombinant mouse M-CSF (R&D Systems) for 6–8 days. At
day 7, the expression of F4/80 (murine macrophage marker) was
examined by fluorescence-activated cell sorting; .90% of cells
were F4/80
+ under these culture conditions.
Preparation of primary murine neuron and glial cultures
Primary neuron, mixed glia and microglia cultures were
prepared from the cerebral cortexes of 1-day-old wild-type or
Stat1
2/2 mice (C57BL/6 background) as previously described
[11,40]. In brief, pooled dissected cortexes were digested in papain
solution (1.5 mM CaCl2, 0.5 mM EDTA, 0.6 mg/ml papain,
0.05 mg/ml DNase I, and 0.2 mg/ml cysteine in Hanks’ balanced
salt solution) at 37uC for 20 min to dissociate the cells. After
centrifugation at 2006g for 5 min, cells were plated on poly-L-
lysine coated (20 mg/ml) dishes. For cortical neuron cultures, cells
were plated in minimal essential medium supplemented with 10%
(v/v) FBS and 10% (v/v) horse serum. One day after seeding, the
culture medium was replaced with neurobasal medium supple-
mented with B27, followed by addition of cytosine arabinoside
(10 mM) on the third and fourth days to inhibit non-neuronal cell
division in vitro. The neuron cultures were used for subsequent
experiments after 10–12 days. For mixed glia culture, cells were
maintained in DMEM/F12 supplemented with 10% (v/v) FCS;
medium was replenished 4 days after plating and changed every 3
days. Cells usually reached confluence within 12–14 days after
plating. For microglia cultures, the confluent mixed glial cells were
incubated with mild trypsin solution (0.25% (w/v) trypsin, 1 mM
EDTA) diluted 1:4 in DMEM/F12 for 30 min at 37uC to detach
the upper layer of astrocytes; 10% (v/v) FCS-containing DMEM/
F12 medium was then added to inactivate trypsin and the
detached astrocytes were aspirated from the mixed glia cultures.
The remaining cells (i.e., microglia) were harvested by incubation
with 0.25% (w/v) trypsin solution with vigorous pipetting for
5 min and then were resuspended in DMEM-F12 with 10% (v/v)
FCS for at least 2 weeks. Cell identity was determined by
immunocytochemical staining using antibodies against tubulin b
III isoform, (TU20; Millipore) for neurons, glial fibrillary acidic
protein (GFAP; Cell Signaling) for astrocytes, and F4/80 for
microglia (Santa Cruz Biotechnology). Mixed glial cultures
contained ,85% astrocytes and ,10% microglia. Neurons and
microglia were .95% pure (Figure S5).
Infection of cells with virus
Human CD14
+-monocyte derived macrophages (MoM), mu-
rine bone-marrow derived macrophages (BMoM), murine mixed
glia and microglial cells were mock-infected or infected with JEV
at a multiplicity of infection 5 (m.o.i.=5). Culture supernatants
were harvested to determine virus titer and cytokine secretion by
plaque assay and ELISA (R&D Systems), respectively. Condi-
tioned media (CM) from mock or JEV-infected mixed glia were
collected and UV-irradiated (254 nm) to inactivate virus. UV-
irradiated CM (UV-JEVCM) was mixed with fresh neurobasal
medium supplemented with B27, before incubation with neuron
cells prior to cytotoxicity assays.
Generation of antagonistic anti-CLEC5A mAbs
Breeder mice (BALB/c strain) were maintained in the standard
animal facility of the National Yang-Ming University. For the
production of mAbs, mice were immunized with purified
recombinant CLEC5A.Fc fusion protein (five doses of 50 mg per
mouse). Lymphocytes from the spleens of immunized mice were
fused with mouse myeloma NS-1 cells in the presence of 50% (v/v)
polyethylene glycol (PEG1450; Sigma). Fused cells were cultured
in HAT selection medium and the medium was refreshed after one
week. About 2 weeks after fusion, culture supernatants were
screened by ELISA to identify the candidate clones for further
analysis by limiting dilution. Anti-CLEC5A mAbs were selected by
ELISA-based differential screening, and only those recognizing
recombinant CLEC5A.Fc, but not human IgG1, were regarded as
ELISA (C) Pooled sera from surviving mice were serially diluted and analyzed using a for the plaque reduction neutralization test (PRNT); data were
collected from four independents experiments with n=5 for each group. (D) INF-c secretion from total splenocytes of surviving mice (recovery, day
21 after JEV infection) after incubation with JEV and UV-JEV for 72 h, but not from mock infected mice. (E) The ability of IFN-c-secreting T-cell was
verified by immobilized anti-CD3 mAb to activate T cells in both mock and JEV-infected (recovery) mice. (F) Viral titers in spleen and brain isolated
from surviving mice after JEV challenge were determined by plaque assay.
doi:10.1371/journal.ppat.1002655.g007
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(m) CLEC5A mAbs. To select antagonistic mAbs against human
CLEC5A and murine CLEC5A, mAbs were incubated with
human macrophages and murine bone marrow-derived macro-
phages (Stat1
2/2), respectively, in 96-well plates (6610
4 cells per
well) for 30 min at 37uC, before the addition of JEV (m.o.i.=5)
and incubation at 37uC for 2 h. After washing, cells were
incubated for a further 36 h before harvesting the supernatants
to measure TNF-a production by ELISA. mAbs capable of
inhibiting cytokine release from JEV-infected macrophages were
used as antagonistic antibodies for in vitro and in vivo assays.
Detection of JEV replication in macrophages and
neuronal cells
To detect JEV replication in macrophages, cells were incubated
with JEV (m.o.i.=5) for 1 h, then fixed with 1% (v/v)
paraformaldehyde and permeabilized with 0.1% (w/v) saponin,
followed by addition of anti-NS3 mAb or isotype-matched control
(mIgG1; Sigma) and then FITC-conjugated goat F(ab)9 anti-
mouse IgG. Emitted fluorescence was detected by flow cytometry
(FACSCalibur platform with CellQuest software (Becton Dick-
inson)). To determine JEV replication, murine neuronal cells were
fixed with 4% (v/v) paraformaldehyde, permeabilized with 0.5%
(v/v) Triton X-100 in PBS for 10 min and incubated with blocking
buffer (10% (w/v) BSA in PBS) before addition of anti-NS3 mAb
(20 mg/ml). After washing, cells were incubated with Cy3-
conjugated donkey anti-mouse IgG (Jackson Immuno) and
Hochest 33342 to detect NS3 and nuclei, respectively. Cover
slips were mounted and observed using an FV-1000 laser scanning
microscope (Olympus).
Immunocytochemical analysis
Cells cultured on coverslips were washed twice with PBS,
followed by incubation with 4% (v/v) paraformaldehyde for 2 h,
and then permeabilized with 0.5% (v/v) Triton X-100 for 15 min.
After washing with PBS, cells were subjected to immunocyto-
chemical staining with HISTOMOUSE-SP KIT (Zymed) accord-
ing to the supplier’s instructions. Briefly, cells were incubated with
primary antibodies (including anti-TU20 (1:300), anti-GFAP
(1:300) or anti-F4/80 (1:500) antibodies for 2 h at room
temperature, followed by incubation with biotinylated secondary
antibody and peroxidase-conjugated streptavidin. Cells were then
incubated with chromogen, and counterstained with hematoxylin
before observation under a light microscope (Nikon).
H&E and immunohistochemical staining
Mice were transcardially perfused with PBS and brains were
removed and placed in 4% (w/v) paraformaldehyde overnight at
4uC, followed by embedding in paraffin wax and processing to
generate 5-micron sagittal sections for H&E staining. Before
immunohistochemical (IHC) staining, paraffin sections were
subjected to antigen retrieval at 100uC for 20 min in 10 mM
citric acid (pH 6.0), and endogenous peroxidase activity was
quenched with 3% (v/v) H2O2 for 15 min at room temperature.
Immunohistochemical staining was performed using a HISTO-
MOUSE-SP KIT (AEC) (Zymed) together with anti-GFAP (1:300)
Ab or mouse JEV-NS3 ascites fluid (1:1000). All images were
digitized with Nikon scientific imaging software.
Administration of antibody to JEV-infected mice
Adult C57BL/6- Stat1
2/2 mice were used in all experimental
procedures. Groups of 8-week-old adult mice were inoculated
intraperitoneally with JEV (strain RP-9; 100 pfu per mouse) [22].
Anti-CLEC5A mAb or isotype control (150 mg per mouse) were
administrated intraperitoneally (i.p.) on days 0, 2, 4, 6 and 8 after
JEV infection, and mice were monitored daily for 16 days to assess
morbidity and mortality. All experiments were performed
according to the animal study protocol approved by the Animal
Experimental Committee of Yang-Ming University.
Isolation of mononuclear cells from the CNS and flow
cytometry analysis
Mononuclear cells (MNCs) were isolated from the brains of
mock- or JEV-infected mice as previously described [41]. Briefly,
PBS-perfused brains were homogenized in HBSS containing 1%
(v/v) FCS and minced with a scalpel before being passed through
an 18-gauge needle. Homogenates were suspended in 37% (w/v)
Percale (4 ml per brain) and overlaid onto 70% (w/v) Percoll
(4 ml) in 15 mL conical tubes; 30% (w/v) Percoll (4 ml) and HBSS
(2 ml) were added prior to centrifugation at 200 g for 40 min at
20uC. After centrifugation, cells were harvested and washed with
PBS to remove residual Percoll. The isolated MNCs were
resuspended in FACS buffer, followed by incubation with
fluorochrome–conjugated anti-CD4, CD8, B220, CD11b,
CD45, F4/80 and CLEC5A mAbs. For intracellular cytokine
staining, cells were fixed with 1% (v/v) paraformaldehyde and
permeabilized with 0.1% (w/v) saponin, before incubation with
specific antibodies. Fluorescence was detected using a FACSCa-
libur platform with CellQuest software (Becton Dickinson).
Blood-brain-barrier (BBB) permeability assay
BBB integrity was evaluated using the Evans blue assay [24].
Mice were injected intravenously with 100 ml of 1% (w/v) Evans
blue in PBS. One hour later, mice were sacrificed and
transcardially perfused with 20 ml of normal saline. Brains were
removed and photographed.
Quantitative real-time PCR analysis
Total RNA was extracted from whole mouse brains using an
RNeasy extraction kit (Qiagen) and complementary DNA (cDNA)
was synthesized by using RevertAid First Strand cDNA Synthesis
Kit (Fermentas, Life Science) according the vendor’s suggestions.
Quantitative real-time PCR analysis was performed using the
LightCycler System SW 3.5.3 (Roche Applied Science) (Fermen-
tas, Life Science), and the level of mRNA expression level was
normalized with b-2 microglobulin. Primer sequences for tight
junction proteins and adhesion molecule: ZO-1, Occludin,
Clauidn-1, Clauidn-5, JAM and ICAM-1 were synthesized as
described previously [24,42]. To quantify the viral copy numbers,
a standard curve was generated using pCR3.1/JEV-39UTR
plasmid as template (ranging from 32 pg/L to 32 mg/L; the
dilution range is equivalent to the copy number 1610 to 1610
7
copies). JEV specific primer: forward 59-AAGTTGAAGGAC-
CAACG-39 (nucleotide 10603–10619); reverse 59-GCATG-
TTGTTGTTTCCAC-39 (nucleotide 10789–10772) [43].
99mTc-DTPA brain SPECT/CT imaging
A FLEX Triumph preclinical imaging system (Gamma Medica-
Ideas, Inc.) was used for the small-animal SPECT/CT scan
acquisition. Each mouse was injected intravenously with
18.5 MBq (0.5 mCi)/0.5 cm
3 of
99mTc-DTPA and images were
acquired 30 min after injection. The mice were scanned first by
CT for anatomic coregistration and then by a dynamic SPECT
sequence comprising 8 frames. The images were viewed and
quantified using AMIDE software (free software provided by
SourceForge). A quantitative index of BBB breakdown was
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disruption of BBB compared with the mean counts/pixel in the
neck muscle.
Plaque reduction neutralization test (PRNT)
To determine the titers of anti-JEV IgM and IgG, serial dilution
of JEV-infected mouse sera were added to immobilized JEV
particles (4610
6 pfu) on microtiter plates, and the bound anti-JEV
specific antibodies were detected with HRP-conjugated anti-
mouse IgM or anti-mouse IgG secondary antibody using TMB as
substrate. The neutralizing activities of mouse sera containing
JEV-specific antibodies were determined using a plaque reduction
neutralization test. Briefly, 100 pfu of JEV were incubated with
serial dilutions of serum samples (20-fold to 200-fold) at 37uC for
1 h, followed by overlaying the virus-serum complex onto BHK21
monolayer. After 1-h adsorption, the virus was removed and
BHK21 cells were overlaid with 1% (w/v) agarose in RPMI-1640
and incubated at 37uC for 72 h. Cells were then fixed with 10%
(w/v) formaldehyde and stained with crystal violet. The neutral-
ization effect was expressed as the percentage reduction in plaque
numbers in the presence of an anti-JEV serum compared to
plaque numbers following infection with JEV (100 pfu) alone [39].
JEV-specific T-cell responses
Total splenocytes from the mock-infected mice and the mice
that recovered from JEV infection (day 21 after JEV infection)
were isolated and seeded in 96-well (5610
5 /well). JEV (PFU=10
and 30) and UV-inactivated JEV were incubated with total
splenocytes for 72 hr, followed by collecting supernatants for IFN-
c measurement. The ability of IFN-c-secreting T cells was verified
by immobilized anti-CD3 mAb to activate T cells.
Generation of CLEC5A KO mice
Mouse Clec5a genomic DNA, 30.7 kb in length (Ensembl
Genomics database) containing exons 1–7, was isolated from a
129/Sv genomic DNA BAC library (CITB mouse; Invitrogen, San
Diego, CA). In order to generate a targeting vector, the Clec5a
genomic DNA fragment was inserted into the pL253 plasmid
containing a neomycin resistance gene allowing antibiotic selection
in ES cells. In the targeting vector, exons 3 to 5 of Clec5a were
flanked by loxP sequences, which could then be excised upon
introduction of a Cre recombinase plasmid into the ES cells.
Excision of exons 3–5 was confirmed by Southern blot analysis of
ES cell genomic DNA, and this was followed by blastocyst injection
to generate Clec5a chimeric mice. Genotyping was performed by
PCR using the following primers: CU, 5-CCCCAGCAT-
CTTTGTTGTTT-3; FD, 5-CCAGCTAGTGGCTCAGTTCC3;
and JD, 5-TTTTCTTCCCCATCCTCTGA-3, which generated a
687-bp WT and a 798-bp knockout (KO) product, respectively. To
obtainStat1andClec5a double-KOmice,we crossed Clec5aKOmice
with Stat1 KO mice [44]. Interbreeding of Clec5a
+/2Stat1
+/2 mice
(F1) generated Clec5a
+/+Stat1
2/2 as well as Clec5a
2/2Stat1
2/2
double KO mice, both of which were used in this study. (Figure S4)
In situ labeling of peripheral blood cells with CFSE
The in situ labeling method was modified from that previously
described [45]. The labeling solution (30 ml of 20 of mM CFSE
(Molecular Probes, Eugene, OR)) was mixed thoroughly with
140 ml of 100% ethyl alcohol and 250 ml pyogen-free PBS to avoid
precipitation. Typically, 8 ml of labeling was injected per gram of
mouse body weight (approximately 3 mg CFSE/g) up to a
maximum of 300 ml of solution. To track leukocyte migration,
mice were injected intraperitoneally with CFSE solution on day 2
after JEV infection. Blood samples were collected from CFSE-
labeled mice to assess the labeling efficiency, and the MNCs in
brain were also harvested from perfused mice to analyze and
distinguish the infiltrating and resident cells in brain on day 5 after
JEV infection. The experimental procedures and labeling control
are shown in supplementary Fig. 6 & 7.
Statistical analysis
Standard errors of the mean (s.e.m.) were calculated and data
was analyzed using unpaired Student’s t-tests. Survival curve
comparisons were performed using log-rank tests (Prism software).
Supporting Information
Figure S1 JEV interacts with CLEC5A and induces
DAP12 phosphorylation via CLEC5A. (A) Expression of
human CLEC5A and an alternatively spliced variant (CLE-
C5A_S) in human microglial cell line (CHME3), monocytic cell
line (U937) and CD14
+-monocyte derived macrophages (MoM)
was detected by RT-PCR. (B) Schematic representation of human
and murine CLEC5A. Sequence analysis of PCR products
revealed that human CLEC5A_S lacks 23 amino acids in the
stalk region (aa 48–70), while mCLEC5A_S lacks 25 amino acids
(aa 28–52) located in stalk regions due to alternative splicing. (C)
JEV–CLEC5A.Fc complexes were immunoprecipitated with
protein A–Sepharose and detected by anti-JEV envelope protein
mAb. (D) JEV-induced DAP12 phosphorylation (1 h post
infection) in human macrophages was determined by western
blotting. (E) Effects of shRNAs (pLL3.7 backbone) on inhibition of
JEV-mediated DAP12 phosphorylation were determined by
western blotting (h.p.i., hours post infection). The pLL3.7/
CLEC4L was used as a control shRNA.
(TIF)
Figure S2 JEV replicates in macrophages and induces
cytokine release. (A) Human MoM and HTB11, (a human
neuroblastoma cell line) infected with DV or JEV (m.o.i.=5) were
subjected to flow cytometry analysis at 48 h post infection using an
antibody to nonstructural protein 3 (NS3) to detect viral antigens.
(B) Murine bone marrow-derived macrophages (BMDM) from wild
typeandStat1
2/2 micewere infected with JEV(m.o.i.=5),followed
by anti JEV-NS3 mAb staining and FACS analysis. (C) BMDM
from Stat1
2/2 mice were infected with DV JEV (m.o.i.=5) in the
absence or presence of different doses of anti-CLEC5A mAbs, and
supernatants were harvested at 48 h post infection for cytokine
determination by ELISA. Data were collected and expressed as
mean 6 s.e.m. from at least three independent experiments. Two-
tailed Student’s t-tests were performed.
(TIF)
Figure S3 Targeting strategy for generation of CLEC5A
KO mice and CLEC5A and STAT1 double KO mice. (A)
Targeting vector for generation of Clec5a
2/2 mice. A neomycin
resistance gene cassette (NEO) was introduced into targeting
vector for positive selection; and two loxP sequences (green
triangles) flanking exons 3 to 5 allow the removal of CLEC5A
exon 3–5 using a Cre-loxP excision system. Locations of PCR
primers used for genotyping are shown under targeting vector. (B)
Genotyping by PCR using CU+FD and CU+JD primer sets for
wild type and Clec5a
2/2 mouse, respectively. (C) Double KO mice
were produced by mating Clec5a
+/+ Stat1
2/2 and Clec5a
2/2
Stat1
+/+ mice, and the F1 offspring were further interbred to
generate F2 offspring. (D) Determination of CLEC5A and STAT1
expression in peripheral blood cells by flow cytometry.
(TIF)
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mixed glia fractions from cerebral cortices. Neurons and
mixed glia were prepared from the cerebral cortices of neonatal
STAT1
2/2 mice, and differentiated in neurobasal medium
supplemented with B27 (Life Technologies) and DMEM/F12
(Life Technologies) supplemented with 10% (v/v) FCS, respec-
tively. Microglia were further enriched from differentiated mixed
glial cell cultures. Neurons, astrocytes and microglia were
characterized by staining with antibodies to tubulin b III isoform,
glial fibrillary acidic protein (GFAP), or F4/80, respectively.
Mixed glial cultures contained ,85% astrocytes and ,10%
microglia. The purity of neurons and microglia was .95%.
(TIF)
Figure S5 Murine models for JEV infection. (A) Wild-type
C57BL/6 mice (n=10 per group) were challenged with various
doses of JEV (pfu) via an intraperitoneal route with intracranial
injection of 30 mL PBS simultaneously (i.p.+i.c.). (B) STAT1-
deficient mice were intraperitoneally infected with a range of doses
of JEV (n=6 per group). All mice were monitored daily for 21
days and outcomes are shown as Kaplan–Meier survival curves
with log rank test.
(TIF)
Figure S6 In situ labeling of peripheral leukocytes with
CFSE in JEV-infected mice. (A) Schematic representation of
the procedure for in situ labeling with CFSE fluorescence dye in
JEV-infected mice. (B) Validation of CFSE labeling efficiency by
analyzing fluorescence intensity in peripheral blood leukocytes
from JEV-infected mice at 72 hr after CFSE injection (day 5 after
JEV infection).
(TIF)
Figure S7 CFSE distribution into CNS after intracranial
puncture. (A) Three modes to evaluate the distribution of CFSE
after i.p. injection to mice with or without intracranial i.c.
puncture. (B) Analysis of CFSE fluorescence in the MNCs isolated
from brain MNCs using Percoll-gradient centrifugation. MFI of
each group was shown in left panel. MFI: mean fluorescence
intensity.
(TIF)
Figure S8 Interactions of CLEC5A with viruses. Various
human viruses (5610
6 pfu/well) were immobilized on microtiter
plates, followed by incubation of CLEC5A.Fc (0.05 mg/ml;
100 ml/well) and HRP-conjugated goat-anti-human IgG. Specific
interactions of CLEC5A with human viruses were determined by
addition of TMB as substrate, and measurement of absorbencies at
450 nm.
(TIF)
Figure S9 WNV replicates in human macrophages and
antagonistic anti-CLEC5A mAbs inhibit WNV-induced
macrophage activation. (A) Human CD14
+-monocyte derived
macrophages (MoM) infected with WNV (m.o.i.=5) were
subjected to flow cytometry analysis at 48 hr post infection using
anti-NS3 antibody to determine WNV replication. (B) Dose-
dependent inhibition of cytokine release from WNV-infected
MoM by anti-CLEC5A mAbs (clones: 3E12A2, 3E1C1 and
9B12H4) determined by ELISA at 48 hr post infection. mIgG1
acts as an isotype matched control. Data were collected from at
least three different donors and expressed as mean 6 s.d. Two-
tailed Student’s t-tests were performed.
(TIF)
Figure S10 Stat1
2/2Clec5a
2/2 mice are resistant to
JEV-infection. Survival of both the Stat1
2/2Clec5a
+/+ and
Stat1
2/2Clec5a
2/2 mice (8–10 weeks) was monitored for 21 days
after i.p. inoculation of JEV (100 pfu/mice); data were collected
from four independent experiments and are shown as Kaplan–
Meier survival curves with log rank test; n=20 for each group.
(TIF)
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